Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

This phase 1, single-center, open-label study explores the safety of escalating doses of chimeric antigen receptor T cells (CAR-T) cells in subjects with relapsed/refractory triple-negative breast cancer (TNBC).

Trial Details

NCT ID
NCT06347068
Phase
PHASE1
Sponsor
UNC Lineberger Comprehensive Cancer Center
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • iC9-CAR.B7-H3 T Cell Therapy
  • cyclophosphamide
  • fludarabine
Locations (sample)
  • Chapel Hill, North Carolina, United States|35.9132,-79.05584

Key Eligibility Criteria

  • Unless otherwise noted, subjects must meet all of the following criteria to participate in in all phases of the study:
  • Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information e…
  • Age ≥ 18 years at the time of consent.
  • Karnofsky score of \> 60% (see APPENDIX VI- Karnofsky Scale))

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →